CD274 and neoplasm: The immunogenic nature of TNBC, as evidenced by a high number of tumor-infiltrating cells and high PD-L1, provides a strong rationale for testing immune checkpoint-blocking therapies; however, currently available data from clinical studies suggest that single-agent immunotherapies have only moderate response rate.